

# CITATION REPORT

List of articles citing

Hippo-independent activation of YAP by the GNAQ1<sup>Q209R</sup> mutant in ocular melanoma oncogene through a trio-regulated rho GTPase signaling circuitry

DOI: 10.1016/j.ccr.2014.04.016  
Cancer Cell, 2014, 25, 831-45.

**Source:** <https://exaly.com/paper-pdf/59749662/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
434	Effects of intra-adrenal infusion of potassium on urinary potassium excretion in the dog. <i>Experimental Biology and Medicine</i> , <b>1960</b> , 104, 764-7	3.7	1
433	The Hippo pathway is controlled by Angiotensin II signaling and its reactivation induces apoptosis in podocytes. <b>2014</b> , 5, e1519		65
432	Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration. <b>2014</b> , 7, ra116		103
431	GNAQ and GNA11 mutations in uveal melanoma. <b>2014</b> , 24, 525-34		75
430	Clinical and histologic findings in patients with uveal melanomas after taking tumor necrosis factor- $\beta$ inhibitors. <b>2014</b> , 89, 1481-6		8
429	Modeling of human uveal melanoma in zebrafish xenograft embryos. <b>2014</b> , 55, 6612-22		56
428	Tg(Grm1) transgenic mice: a murine model that mimics spontaneous uveal melanoma in humans?. <b>2014</b> , 127, 59-68		26
427	The biology of YAP/TAZ: hippo signaling and beyond. <b>2014</b> , 94, 1287-312		907
426	Sensing the local environment: actin architecture and Hippo signalling. <b>2014</b> , 31, 74-83		105
425	GNAQ/11 mutations in uveal melanoma: is YAP the key to targeted therapy?. <i>Cancer Cell</i> , <b>2014</b> , 25, 714-524.3		29
424	Biology of advanced uveal melanoma and next steps for clinical therapeutics. <i>Pigment Cell and Melanoma Research</i> , <b>2015</b> , 28, 135-47	4.5	62
423	The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression. <b>2015</b> , 7, 1426-49		147
422	Current State of Animal (Mouse) Modeling in Melanoma Research. <b>2015</b> , 8, 81-94		60
421	Upcoming translational challenges for uveal melanoma. <b>2015</b> , 113, 1249-53		16
420	A Novel Model of Metastatic Conjunctival Melanoma in Immune-Competent Mice. <b>2015</b> , 56, 5965-73		9
419	A Subset of Nuclear Receptors are Uniquely Expressed in Uveal Melanoma Cells. <b>2015</b> , 6, 93		4
418	Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. <b>2015</b> , 6, 36041-52		71

417	Mechanical stress regulates gene expression via Rho/Rho-kinase signaling pathway. <b>2015</b> , 4, 53-61	3
416	Netrin-1 exerts oncogenic activities through enhancing Yes-associated protein stability. <b>2015</b> , 112, 7255-60	26
415	YAP and TAZ: a nexus for Hippo signaling and beyond. <b>2015</b> , 25, 499-513	335
414	The Hippo pathway effector YAP controls mouse hepatic stellate cell activation. <b>2015</b> , 63, 679-88	199
413	YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations. <b>2015</b> , 2, e970957	15
412	Mutant GNAQ promotes cell viability and migration of uveal melanoma cells through the activation of Notch signaling. <b>2015</b> , 34, 295-301	10
411	Melanotic tumors of the nervous system are characterized by distinct mutational, chromosomal and epigenomic profiles. <b>2015</b> , 25, 202-8	54
410	The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. <b>2015</b> , 47, 250-6	320
409	The emerging roles of YAP and TAZ in cancer. <b>2015</b> , 15, 73-79	705
408	An update on ocular melanoma. <b>2015</b> , 21, 19-25	3
407	Avalanching mutations in biallelic mismatch repair deficiency syndrome. <b>2015</b> , 47, 194-6	3
406	YAP and the drug resistance highway. <b>2015</b> , 47, 193-4	31
405	The regulation and function of YAP transcription co-activator. <b>2015</b> , 47, 16-28	80
404	G protein-coupled receptors: bridging the gap from the extracellular signals to the Hippo pathway. <b>2015</b> , 47, 10-5	15
403	Disease implications of the Hippo/YAP pathway. <b>2015</b> , 21, 212-22	157
402	Genetic landscape of uveal melanoma. <b>2015</b> , 38, 522-5	6
401	Opposing roles of conventional and novel PKC isoforms in Hippo-YAP pathway regulation. <b>2015</b> , 25, 985-8	34
400	The Hippo signal transduction pathway in soft tissue sarcomas. <b>2015</b> , 1856, 121-9	23

399	Oncogenic G Protein GNAQ Induces Uveal Melanoma and Intravasation in Mice. <b>2015</b> , 75, 3384-97	61
398	G Protein-Coupled Receptor and RhoA-Stimulated Transcriptional Responses: Links to Inflammation, Differentiation, and Cell Proliferation. <b>2015</b> , 88, 171-80	67
397	Primary melanocytic tumors of the central nervous system: a review with focus on molecular aspects. <b>2015</b> , 25, 209-26	64
396	Growth control: re-examining Zyxin's role in the hippo pathway. <b>2015</b> , 25, R230-R231	3
395	Melanoma. <b>2015</b> , 1, 15003	283
394	Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. <b>2015</b> , 163, 811-28	1185
393	Alternative Wnt Signaling Activates YAP/TAZ. <b>2015</b> , 162, 780-94	393
392	A miR-130a-YAP positive feedback loop promotes organ size and tumorigenesis. <b>2015</b> , 25, 997-1012	68
391	MST kinases in development and disease. <b>2015</b> , 210, 871-82	100
390	Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1. <b>2015</b> , 8, ra98	114
389	Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT). <b>2015</b> , 15, 467	38
388	Competing to coordinate cell fate decisions: the MST2-Raf-1 signaling device. <b>2015</b> , 14, 189-99	21
387	The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1. <b>2015</b> , 25, 1299-313	115
386	The mammalian Hippo pathway: regulation and function of YAP1 and TAZ. <b>2015</b> , 72, 285-306	70
385	Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway. <b>2015</b> , 34, 3536-46	49
384	Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy. <b>2016</b> , 7,	38
383	Emerging role of Hippo pathway in gastric and other gastrointestinal cancers. <b>2016</b> , 22, 1279-88	43
382	Gnaq and Gna11 in the Endothelin Signaling Pathway and Melanoma. <b>2016</b> , 7, 59	22

381	G Protein-Coupled Receptors in Cancer. <b>2016</b> , 17,	108
380	YAP promotes erlotinib resistance in human non-small cell lung cancer cells. <b>2016</b> , 7, 51922-51933	71
379	The role of mitogen-activated protein targeting in melanoma beyond BRAFV600. <b>2016</b> , 28, 185-91	13
378	YAP/TAZ as therapeutic targets in cancer. <b>2016</b> , 29, 26-33	126
377	Uveal melanoma: From diagnosis to treatment and the science in between. <b>2016</b> , 122, 2299-312	166
376	PAUPAR lncRNA suppresses tumorigenesis by H3K4 demethylation in uveal melanoma. <b>2016</b> , 590, 1729-38	29
375	Class III-specific HDAC inhibitor Tenovin-6 induces apoptosis, suppresses migration and eliminates cancer stem cells in uveal melanoma. <b>2016</b> , 6, 22622	54
374	YAP overexpression promotes the epithelial-mesenchymal transition and chemoresistance in pancreatic cancer cells. <b>2016</b> , 13, 237-42	56
373	Lineage Segregation in the Totipotent Embryo. <b>2016</b> , 117, 301-17	10
372	YAP Mediates Tumorigenesis in Neurofibromatosis Type 2 by Promoting Cell Survival and Proliferation through a COX-2-EGFR Signaling Axis. <b>2016</b> , 76, 3507-19	32
371	Somatic Activating Mutations in GNAQ and GNA11 Are Associated with Congenital Hemangioma. <b>2016</b> , 98, 789-95	102
370	The G protein G $\beta$ acts as a tumor suppressor in sonic hedgehog signaling-driven tumorigenesis. <b>2016</b> , 15, 1325-30	22
369	Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives. <b>2016</b> , 12, 1331-44	22
368	The Hippo pathway in intestinal regeneration and disease. <b>2016</b> , 13, 324-37	139
367	Hijacking GPCRs by viral pathogens and tumor. <b>2016</b> , 114, 69-81	15
366	Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation. <b>2016</b> , 35, 462-78	132
365	Cellular functions of the ADF/cofilin family at a glance. <b>2016</b> , 129, 3211-8	123
364	The roles of the Hippo pathway in cancer metastasis. <b>2016</b> , 28, 1761-72	61

363	Role of Src Family Kinases in Regulation of Intestinal Epithelial Homeostasis. <b>2016</b> , 36, 2811-2823		17
362	Analysis of the Expression and Single-Nucleotide Variant Frequencies of the Butyrophilin-like 2 Gene in Patients With Uveal Melanoma. <b>2016</b> , 134, 1125-1133		7
361	GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis. <b>2016</b> , 65, 156-63		43
360	Regulation of TAZ in cancer. <b>2016</b> , 7, 548-61		27
359	WIP Drives Tumor Progression through YAP/TAZ-Dependent Autonomous Cell Growth. <b>2016</b> , 17, 1962-1977		34
358	Integrin-mediated mechanotransduction. <b>2016</b> , 215, 445-456		469
357	UNR/CSDE1 Drives a Post-transcriptional Program to Promote Melanoma Invasion and Metastasis. <i>Cancer Cell</i> , <b>2016</b> , 30, 694-707	24.3	83
356	Update on Ophthalmic Oncology 2014: Retinoblastoma and Uveal Melanoma. <b>2016</b> , 5, 368-82		4
355	ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma. <i>Cancer Cell</i> , <b>2016</b> , 29, 889-904	24.3	86
354	YAP/TAZ at the Roots of Cancer. <i>Cancer Cell</i> , <b>2016</b> , 29, 783-803	24.3	886
353	GEP oncogene promotes cell proliferation through YAP activation in ovarian cancer. <b>2016</b> , 35, 4471-80		27
352	RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non-Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway. <b>2016</b> , 76, 1627-40		68
351	Update on Metastatic Uveal Melanoma: Progress and Challenges. <b>2016</b> , 30, 161-72		11
350	Selumetinib for the treatment of melanoma. <b>2016</b> , 4, 223-231		
349	Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma. <b>2016</b> , 18, 6		19
348	Myocardin-Related Transcription Factor A and Yes-Associated Protein Exert Dual Control in G Protein-Coupled Receptor- and RhoA-Mediated Transcriptional Regulation and Cell Proliferation. <b>2016</b> , 36, 39-49		59
347	Control of YAP/TAZ Activity by Metabolic and Nutrient-Sensing Pathways. <b>2016</b> , 26, 289-299		101
346	Mechanisms of Hippo pathway regulation. <b>2016</b> , 30, 1-17		834

345	Inactivating mutations in GNA13 and RHOA in Burkitt's lymphoma and diffuse large B-cell lymphoma: a tumor suppressor function for the G13/RhoA axis in B cells. <b>2016</b> , 35, 3771-80	51
344	Role of YAP/TAZ in cell-matrix adhesion-mediated signalling and mechanotransduction. <b>2016</b> , 343, 42-53	247
343	Control of Proliferation and Cancer Growth by the Hippo Signaling Pathway. <b>2016</b> , 14, 127-40	97
342	YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. <b>2016</b> , 35, 1541-53	80
341	Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. <b>2017</b> , 16, 516-528	42
340	Multiparametric Analysis of Cell Shape Demonstrates that EPIX Directly Couples YAP Activation to Extracellular Matrix Adhesion. <b>2017</b> , 4, 84-96.e6	33
339	Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma. <b>2017</b> , 15, 501-506	49
338	The biology of uveal melanoma. <b>2017</b> , 36, 109-140	101
337	Amotl1 mediates sequestration of the Hippo effector Yap1 downstream of Fat4 to restrict heart growth. <i>Nature Communications</i> , <b>2017</b> , 8, 14582	17.4 56
336	Focus on cutaneous and uveal melanoma specificities. <b>2017</b> , 31, 724-743	55
335	RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma. <i>Cancer Cell</i> , <b>2017</b> , 31, 685-696.e6	24.3 73
334	Targeting YAP in malignant pleural mesothelioma. <b>2017</b> , 21, 2663-2676	37
333	A reciprocal regulatory loop between TAZ/YAP and G-protein G12 regulates Schwann cell proliferation and myelination. <i>Nature Communications</i> , <b>2017</b> , 8, 15161	17.4 49
332	Genetically engineered mouse models of melanoma. <b>2017</b> , 123, 2089-2103	45
331	Flow-Dependent Endothelial YAP Regulation Contributes to Vessel Maintenance. <b>2017</b> , 40, 523-536.e6	157
330	ZEB1 Regulates Multiple Oncogenic Components Involved in Uveal Melanoma Progression. <b>2017</b> , 7, 45	27
329	MRTF potentiates TEAD-YAP transcriptional activity causing metastasis. <b>2017</b> , 36, 520-535	63
328	Nerve Growth Factor Promotes Gastric Tumorigenesis through Aberrant Cholinergic Signaling. <i>Cancer Cell</i> , <b>2017</b> , 31, 21-34	24.3 201

327	β1 integrin-dependent Rac/group I PAK signaling mediates YAP activation of Yes-associated protein 1 (YAP1) via NF2/merlin. <i>Journal of Biological Chemistry</i> , <b>2017</b> , 292, 19179-19197	5-4	64
326	Mechanobiology of YAP and TAZ in physiology and disease. <b>2017</b> , 18, 758-770		513
325	Rho differentially regulates the Hippo pathway by modulating the interaction between Amot and NF2 in the blastocyst. <b>2017</b> , 144, 3957-3967		22
324	[Ocular melanomas : An update]. <b>2017</b> , 38, 491-499		4
323	Flow pattern-dependent endothelial cell responses through transcriptional regulation. <b>2017</b> , 16, 1893-1901		43
322	Mechanobiology of limb musculoskeletal development. <b>2017</b> , 1409, 18-32		31
321	Src Inhibits the Hippo Tumor Suppressor Pathway through Tyrosine Phosphorylation of Lats1. <b>2017</b> , 77, 4868-4880		79
320	Recent advances in uveal melanoma treatment. <b>2017</b> , 37, 1350-1372		19
319	Mechanosensing in liver regeneration. <b>2017</b> , 71, 153-167		26
318	Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies. <b>2017</b> , 74, 1457-1474		62
317	RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3. <b>2017</b> , 36, 999-1011		19
316	Ras and the Hippo Pathway in Cancer. <b>2017</b> , 25-39		
315	Uveal Melanoma: Identifying Immunological and Chemotherapeutic Targets to Treat Metastases. <b>2017</b> , 6, 179-185		10
314	Regulation of Tissue Growth by the Mammalian Hippo Signaling Pathway. <b>2017</b> , 8, 942		29
313	Insights into the Regulation of Yap/Taz from Cellular Systems and Mouse Models. <b>2018</b> , 13, 16-25		
312	The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma and. <b>2017</b> , 7, 1447-1462		37
311	Uveal melanoma: epidemiology, etiology, and treatment of primary disease. <b>2017</b> , 11, 279-289		147
310	Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma. <b>2017</b> , 58, 3464-3470		27



309	Epidermal loss of G $\beta$ confers a migratory and differentiation defect in keratinocytes. <b>2017</b> , 12, e0173692		7
308	Producing tissue specific stem cells for regeneration: how YAP/TAZ may prove useful. <b>2017</b> , 4, 16		1
307	Treatment of uveal melanoma: where are we now?. <b>2018</b> , 10, 1758834018757175		136
306	GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma. <b>2018</b> , 22, 2455-2468		49
305	PRDM4 mediates YAP-induced cell invasion by activating leukocyte-specific integrin $\beta$ expression. <b>2018</b> , 19,		25
304	Hippo-yap signaling in ocular development and disease. <b>2018</b> , 247, 794-806		14
303	Uveal melanoma driver mutations in GNAQ/11 yield numerous changes in melanocyte biology. <i>Pigment Cell and Melanoma Research</i> , <b>2018</b> , 31, 604-613	4-5	14
302	Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model. <b>2018</b> , 22, 3073-3085		16
301	Regulation of RhoA GTPase and various transcription factors in the RhoA pathway. <b>2018</b> , 233, 6381-6392		55
300	YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma. <b>2018</b> , 6, 255-266		91
299	The $\beta$ arrestin ARRDC3 suppresses breast carcinoma invasion by regulating G protein-coupled receptor lysosomal sorting and signaling. <i>Journal of Biological Chemistry</i> , <b>2018</b> , 293, 3350-3362	5-4	24
298	The Hippo pathway in normal development and cancer. <b>2018</b> , 186, 60-72		85
297	Genetics of metastasis: melanoma and other cancers. <b>2018</b> , 35, 379-391		33
296	VEGF-neuropilin-2 signaling promotes stem-like traits in breast cancer cells by TAZ-mediated repression of the Rac GAP $\beta$ -chimaerin. <b>2018</b> , 11,		34
295	Regulation of the Hippo pathway in cancer biology. <b>2018</b> , 75, 2303-2319		42
294	Cell Junctions in Hippo Signaling. <b>2018</b> , 10,		49
293	Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors. <b>2018</b> , 37, 944-952		32
292	Kinome-wide transcriptional profiling of uveal melanoma reveals new vulnerabilities to targeted therapeutics. <i>Pigment Cell and Melanoma Research</i> , <b>2018</b> , 31, 253-266	4-5	7

291	Genetic and epigenetic insights into uveal melanoma. <b>2018</b> , 93, 952-961		25
290	Tissue inhibitor of metalloproteinase-1 promotes cell proliferation through YAP/TAZ activation in cancer. <b>2018</b> , 37, 263-270		23
289	Paving the Rho in cancer metastasis: Rho GTPases and beyond. <b>2018</b> , 183, 1-21		93
288	GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells. <b>2018</b> , 32, 1170-1183		47
287	Therapeutic targeting of oncogenic transcription factors by natural products in eye cancer. <b>2018</b> , 129, 365-374		6
286	Cancer driver G-protein coupled receptor (GPCR) induced $\beta$ -catenin nuclear localization: the transcriptional junction. <b>2018</b> , 37, 147-157		9
285	Deregulation and Therapeutic Potential of the Hippo Pathway in Cancer. <b>2018</b> , 2, 59-79		13
284	Upstairs, downstairs: spatial regulation of Hippo signalling. <b>2018</b> , 51, 22-32		48
283	Animal Models of Melanoma. <b>2018</b> , 1-31		1
282	Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma. <b>2018</b> , 2018,		32
281	Cyclopeptide RA-V Inhibits Organ Enlargement and Tumorigenesis Induced by YAP Activation. <i>Cancers</i> , <b>2018</b> , 10,	6.6	9
280	The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer. <b>2018</b> , 6,		20
279	CircFAT1 sponges miR-375 to promote the expression of Yes-associated protein 1 in osteosarcoma cells. <b>2018</b> , 17, 170		82
278	Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling. <i>Journal of Biological Chemistry</i> , <b>2018</b> , 293, 18230-18241	5-4	36
277	Atypical activation of the G protein G $\beta$ by the oncogenic mutation Q209P. <i>Journal of Biological Chemistry</i> , <b>2018</b> , 293, 19586-19599	5-4	14
276	Convergence of VEGF and YAP/TAZ signaling: Implications for angiogenesis and cancer biology. <b>2018</b> , 11,		44
275	Targeted Therapy in Advanced Melanoma. <b>2018</b> , 1-20		
274	The role of YAP/TAZ activity in cancer metabolic reprogramming. <b>2018</b> , 17, 134		58

273	Zyxin promotes colon cancer tumorigenesis in a mitotic phosphorylation-dependent manner and through CDK8-mediated YAP activation. <b>2018</b> , 115, E6760-E6769		21
272	Hippo signaling dysfunction induces cancer cell addiction to YAP. <b>2018</b> , 37, 6414-6424		15
271	Interplay between YAP/TAZ and Metabolism. <b>2018</b> , 28, 196-206		137
270	YAP/TAZ upstream signals and downstream responses. <b>2018</b> , 20, 888-899		350
269	The Role of the RhoA/ROCK Signaling Pathway in Mechanical Strain-Induced Scleral Myofibroblast Differentiation. <b>2018</b> , 59, 3619-3629		22
268	STARD13-correlated ceRNA network-directed inhibition on YAP/TAZ activity suppresses stemness of breast cancer via co-regulating Hippo and Rho-GTPase/F-actin signaling. <b>2018</b> , 11, 72		81
267	Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma. <i>Cancers</i> , <b>2018</b> , 10,	6.6	21
266	YAP/TAZ Activation as a Target for Treating Metastatic Cancer. <i>Cancers</i> , <b>2018</b> , 10,	6.6	87
265	Genome-Wide Methylation Patterns in Androgen-Independent Prostate Cancer Cells: A Comprehensive Analysis Combining MeDIP-Bisulfite, RNA, and microRNA Sequencing Data. <b>2018</b> , 9,		3
264	Assembly and activation of the Hippo signalome by FAT1 tumor suppressor. <i>Nature Communications</i> , <b>2018</b> , 9, 2372	17.4	62
263	GPCRs in Cancer: Protease-Activated Receptors, Endocytic Adaptors and Signaling. <b>2018</b> , 19,		46
262	Oncogenic signaling in uveal melanoma. <i>Pigment Cell and Melanoma Research</i> , <b>2018</b> , 31, 661-672	4.5	36
261	Digital PCR-Based T-cell Quantification-Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma. <b>2018</b> , 16, 1902-1911		24
260	Key Signaling Pathways in Normal and Neoplastic Melanocytes. <b>2018</b> , 1-19		
259	Uveal Melanoma. <b>2018</b> , 273-312		2
258	YAP and MRTF-A, transcriptional co-activators of RhoA-mediated gene expression, are critical for glioblastoma tumorigenicity. <b>2018</b> , 37, 5492-5507		35
257	Targeting the Hippo Pathway to Improve Response to Chemotherapy. <b>2019</b> , 169-185		1
256	Targeted Therapy in Advanced Melanoma. <b>2019</b> , 667-686		

255	Key Signaling Pathways in Normal and Neoplastic Melanocytes. <b>2019</b> , 63-81		
254	Molecular Genetics of Melanocytic Neoplasia. <b>2019</b> , 123-145		1
253	Melanomics: Comprehensive Molecular Analysis of Normal and Neoplastic Melanocytes. <b>2019</b> , 181-224		
252	Animal Models of Melanoma. <b>2019</b> , 303-333		
251	DLC1 deficiency and YAP signaling drive endothelial cell contact inhibition of growth and tumorigenesis. <b>2019</b> , 38, 7046-7059		5
250	The Hippo Signaling Pathway in Development and Disease. <b>2019</b> , 50, 264-282		254
249	Animal Models in Uveal Melanoma. <b>2019</b> , 135-154		1
248	Arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer. <i>Nature Communications</i> , <b>2019</b> , 10, 3196	17.4	24
247	Emerging Therapeutic Opportunities Based on Current Knowledge of Uveal Melanoma Biology. <i>Cancers</i> , <b>2019</b> , 11,	6.6	19
246	So Close, yet so Far: Discrepancies between Uveal and Other Melanomas. A Position Paper from UM Cure 2020. <i>Cancers</i> , <b>2019</b> , 11,	6.6	28
245	Molecular Characteristics of Uveal Melanoma: Insights from the Cancer Genome Atlas (TCGA) Project. <i>Cancers</i> , <b>2019</b> , 11,	6.6	30
244	Nanoparticle-Based Hybrid Scaffolds for Deciphering the Role of Multimodal Cues in Cardiac Tissue Engineering. <b>2019</b> , 13, 12525-12539		44
243	Control of cellular responses to mechanical cues through YAP/TAZ regulation. <i>Journal of Biological Chemistry</i> , <b>2019</b> , 294, 17693-17706	5.4	98
242	MK5 Regulates YAP Stability and Is a Molecular Target in YAP-Driven Cancers. <b>2019</b> , 79, 6139-6152		12
241	The Role of Stiffness in Cell Reprogramming: A Potential Role for Biomaterials in Inducing Tissue Regeneration. <b>2019</b> , 8,		43
240	CCT3 acts upstream of YAP and TFCP2 as a potential target and tumour biomarker in liver cancer. <b>2019</b> , 10, 644		21
239	Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma. <b>2019</b> , 18, 140		23
238	Hippo signalling during development. <b>2019</b> , 146,		32

237	Gβ-mediated LATS1 down-regulation contributes to epithelial-mesenchymal transition in ovarian cancer. <b>2019</b> , 33, 13683-13694		8
236	Lens Stretching Modulates Lens Epithelial Cell Proliferation via YAP Regulation. <b>2019</b> , 60, 3920-3929		15
235	The Efficiency of Verteporfin as a Therapeutic Option in Pre-Clinical Models of Melanoma. <b>2019</b> , 10, 1-10		19
234	Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities. <b>2019</b> , 5, 297-307		113
233	Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer. <i>Cancers</i> , <b>2019</b> , 11,	6.6	4
232	Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives. <i>Cancers</i> , <b>2019</b> , 11,	6.6	39
231	HDAC Inhibition Enhances the Efficacy of MEK Inhibitor Therapy in Uveal Melanoma. <b>2019</b> , 25, 5686-5701		42
230	YAP promotes neural crest emigration through interactions with BMP and Wnt activities. <b>2019</b> , 17, 69		23
229	Switch-like enhancement of epithelial-mesenchymal transition by YAP through feedback regulation of WT1 and Rho-family GTPases. <i>Nature Communications</i> , <b>2019</b> , 10, 2797	17.4	55
228	Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy. <i>Journal of Biological Chemistry</i> , <b>2019</b> , 294, 11062-11086	5.4	73
227	PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma. <i>Cancers</i> , <b>2019</b> , 11,	6.6	19
226	MITF-the first 25 years. <b>2019</b> , 33, 983-1007		125
225	Increased elasticity of melanoma cells after low-LET proton beam due to actin cytoskeleton rearrangements. <b>2019</b> , 9, 7008		5
224	Uveal melanoma: physiopathology and new in situ-specific therapies. <b>2019</b> , 84, 15-32		20
223	Direct targeting of Gβ and Gβ oncoproteins in cancer cells. <b>2019</b> , 12,		53
222	Somatic Hypermutation of the Oncogene in a Human Cutaneous Melanoma. <b>2019</b> , 17, 1435-1449		15
221	Integrin α1 in pancreatic stellate cells regulates tumor stroma interaction in pancreatic cancer. <b>2019</b> , 33, 6609-6621		29
220	F-actin dynamics regulates mammalian organ growth and cell fate maintenance. <b>2019</b> , 71, 130-142		32

219	YAP/TAZ Signaling and Resistance to Cancer Therapy. <b>2019</b> , 5, 283-296		83
218	Mechanotransduction and Cytoskeleton Remodeling Shaping YAP1 in Gastric Tumorigenesis. <b>2019</b> , 20,		13
217	Structure of the C-terminal guanine nucleotide exchange factor module of Trio in an autoinhibited conformation reveals its oncogenic potential. <b>2019</b> , 12,		12
216	A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK. <i>Cancer Cell</i> , <b>2019</b> , 35, 457-472.e5	24.3	93
215	Salinomycin effectively eliminates cancer stem-like cells and obviates hepatic metastasis in uveal melanoma. <b>2019</b> , 18, 159		19
214	YAP/TAZ Activation Drives Uveal Melanoma Initiation and Progression. <b>2019</b> , 29, 3200-3211.e4		24
213	Uveal Melanoma. <i>Cancers</i> , <b>2019</b> , 11,	6.6	1
212	Effects of Oncogenic G $\beta$ and G $\beta$ Inhibition by FR900359 in Uveal Melanoma. <b>2019</b> , 17, 963-973		39
211	Unbalanced YAP-SOX9 circuit drives stemness and malignant progression in esophageal squamous cell carcinoma. <b>2019</b> , 38, 2042-2055		42
210	The fibrinolytic factor tPA drives LRP1-mediated melanoma growth and metastasis. <b>2019</b> , 33, 3465-3480		12
209	Selective PKC $\beta$ Inhibitor B106 Elicits Uveal Melanoma Growth Inhibitory Effects Independent of Activated PKC Isoforms. <b>2019</b> , 14, 132-136		3
208	Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine. <b>2019</b> , 20, 211-226		253
207	Frequent and Yet Unreported GNAQ and GNA11 Mutations are Found in Uveal Melanomas. <b>2019</b> , 25, 1319-1325		11
206	The small GTPase ARF6 regulates protein trafficking to control cellular function during development and in disease. <b>2019</b> , 10, 1-12		11
205	Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway. <b>2020</b> , 11, 280-288		14
204	Uveal melanoma: Towards a molecular understanding. <b>2020</b> , 75, 100800		58
203	Hippo-Yap/Taz signaling: Complex network interactions and impact in epithelial cell behavior. <b>2020</b> , 9, e371		7
202	Inhibition of cyclin-dependent kinase 7 down-regulates yes-associated protein expression in mesothelioma cells. <b>2020</b> , 24, 1087-1098		6

201	Cell-permeable high-affinity tracers for G proteins provide structural insights, reveal distinct binding kinetics and identify small molecule inhibitors. <b>2020</b> , 177, 1898-1916		12
200	Mouse models of uveal melanoma: Strengths, weaknesses, and future directions. <i>Pigment Cell and Melanoma Research</i> , <b>2020</b> , 33, 264-278	4.5	11
199	GF1 directly drives PDZ-RhoGEF signaling to Cdc42. <i>Journal of Biological Chemistry</i> , <b>2020</b> , 295, 16920-16928	5.4	8
198	FoxM1 insufficiency hyperactivates Ect2-RhoA-mDia1 signaling to drive cancer. <b>2020</b> , 1, 1010-1024		2
197	Hippo signaling promotes Ets2-dependent apical cell extrusion in the wing disc. <b>2020</b> , 147,		3
196	Unpacking the genetic etiology of uveal melanoma. <b>2020</b> , 15, 211-220		2
195	Overcoming Immune Evasion in Melanoma. <b>2020</b> , 21,		29
194	G Protein-Coupled receptors and heterotrimeric G proteins as cancer drivers. <b>2020</b> , 594, 4201-4232		24
193	Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in Tumorigenesis. <i>Cancers</i> , <b>2020</b> , 12,	6.6	6
192	Novel Approaches to the Systemic Management of Uveal Melanoma. <b>2020</b> , 22, 104		5
191	MicroRNAs and Uveal Melanoma: Understanding the Diverse Role of These Small Molecular Regulators. <b>2020</b> , 21,		11
190	YAP and TAZ protect against white adipocyte cell death during obesity. <i>Nature Communications</i> , <b>2020</b> , 11, 5455	17.4	8
189	Contributions of Yap and Taz dysfunction to breast cancer initiation, progression, and aging-related susceptibility. <b>2020</b> , 1, 5-18		0
188	Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications. <b>2020</b> , 7, 172		14
187	Chloroquine Sensitizes -mutated Melanoma to MEK1/2 Inhibition. <b>2020</b> , 26, 6374-6386		15
186	Uncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives. <i>Cancers</i> , <b>2020</b> , 12,	6.6	10
185	Publication trends of research on uveal melanoma during 2000-2020: a 20-year bibliometric study. <b>2020</b> , 8, 1463		2
184	Monosomy-3 Alters the Expression Profile of the Glucose Transporters GLUT1-3 in Uveal Melanoma. <b>2020</b> , 21,		1

183	Uveal melanoma: progress in molecular biology and therapeutics. <b>2020</b> , 12, 1758835920965852		12
182	Computational models of melanoma. <b>2020</b> , 17, 8		4
181	Hyaluronan Degradation Promotes Cancer via Hippo-YAP Signaling: An Intervention Point for Cancer Therapy. <b>2020</b> , 42, e2000005		1
180	The Hippo Pathway as a Driver of Select Human Cancers. <b>2020</b> , 6, 781-796		13
179	Update on Alterations in Cancer: Implications for Uveal Melanoma Treatment. <i>Cancers</i> , <b>2020</b> , 12,	6.6	8
178	Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. <b>2020</b> , 19, 480-494		119
177	Dabigatran ameliorates airway smooth muscle remodeling in asthma by modulating Yes-associated protein. <b>2020</b> , 24, 8179-8193		4
176	Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma. <b>2020</b> , 13, 77		24
175	A Driver Never Works Alone-Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	2
174	The Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis. <b>2020</b> , 39, 5267-5281		16
173	Clinicopathological and prognostic significance and molecular mechanisms governing uveal melanoma. <b>2020</b> , 12, 1758835920917566		4
172	A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. <b>2020</b> , 10, 3622-3635		58
171	Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers?. <i>Cancers</i> , <b>2020</b> , 12,	6.6	10
170	Mechanical stress triggers nuclear remodeling and the formation of transmembrane actin nuclear lines with associated nuclear pore complexes. <b>2020</b> , 31, 1774-1787		25
169	Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma. <b>2020</b> , 126, 93-103		11
168	Mechanical force regulation of YAP by F-actin and GPCR revealed by super-resolution imaging. <b>2020</b> , 12, 2703-2714		15
167	Der Hippo-Signalweg in der Regeneration und im Krebs. <b>2020</b> , 26, 154-157		
166	Uveal melanoma. <b>2020</b> , 6, 24		143



165	YAP Activity is Not Associated with Survival of Uveal Melanoma Patients and Cell Lines. <b>2020</b> , 10, 6209	8
164	GPR39 Overexpression in OSCC Promotes YAP-Sustained Malignant Progression. <b>2020</b> , 99, 949-958	6
163	Targeting Rac and Cdc42 GEFs in Metastatic Cancer. <b>2020</b> , 8, 201	34
162	Ubiquitin-proteasome system-targeted therapy for uveal melanoma: what is the evidence?. <b>2021</b> , 42, 179-188	4
161	A case series of tardive expansion congenital hemangioma: A variation of noninvoluting congenital hemangioma or a new hemangiomatous entity?. <b>2021</b> , 84, 1371-1377	3
160	SHANK2 is a frequently amplified oncogene with evolutionarily conserved roles in regulating Hippo signaling. <b>2021</b> , 12, 174-193	3
159	The Hippo Pathway in Liver Homeostasis and Pathophysiology. <b>2021</b> , 16, 299-322	25
158	Tumor microenvironment as a therapeutic target in cancer. <b>2021</b> , 221, 107753	41
157	Nuclear exclusion of YAP exacerbates podocyte apoptosis and disease progression in Adriamycin-induced focal segmental glomerulosclerosis. <b>2021</b> , 101, 258-270	2
156	An RGDKGE-Containing Cryptic Collagen Fragment Regulates Phosphorylation of Large Tumor Suppressor Kinase-1 and Controls Ovarian Tumor Growth by a Yes-Associated Protein-Dependent Mechanism. <b>2021</b> , 191, 527-544	1
155	Functional characterization of uveal melanoma oncogenes. <b>2021</b> , 40, 806-820	9
154	Heterogeneity of GNAQ/11 mutation inversely correlates with the metastatic rate in uveal melanoma. <b>2021</b> , 105, 587-592	2
153	The Hippo Tumor Suppressor Pathway (YAP/TAZ/TEAD/MST/LATS) and EGFR-RAS-RAF-MEK in cancer metastasis. <b>2021</b> , 8, 48-60	9
152	The RGS-RhoGEFs control the amplitude of YAP1 activation by serum. <b>2021</b> , 11, 2348	0
151	The Roles of Anoikis in Cervical Cancer. <b>2021</b> , 127-136	
150	miR-582-5p Is a Tumor Suppressor microRNA Targeting the Hippo-YAP/TAZ Signaling Pathway in Non-Small Cell Lung Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6 11
149	Verteporfin induces apoptosis and reduces the stem cell-like properties in Neuroblastoma tumour-initiating cells through inhibition of the YAP/TAZ pathway. <b>2021</b> , 893, 173829	4
148	Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for -Driven Uveal Melanoma. <b>2021</b> , 27, 3190-3200	12

147	Uveal melanoma cells use ameoid and mesenchymal mechanisms of cell motility crossing the endothelium. <b>2021</b> , 32, 413-421	4
146	Translation of single-cell transcriptomic analysis of uveal melanomas to clinical oncology. <b>2021</b> , 85, 100968	8
145	Selective targeting of KRAS-driven lung tumorigenesis via unresolved ER stress. <b>2021</b> , 6,	0
144	Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin. <b>2021</b> , 62, 3	5
143	RhoA: a dubious molecule in cardiac pathophysiology. <b>2021</b> , 28, 33	6
142	LACTB suppresses melanoma progression by attenuating PP1A and YAP interaction. <b>2021</b> , 506, 67-82	8
141	Anti-tumor effect of trametinib in bladder cancer organoid and the underlying mechanism. <b>2021</b> , 22, 357-371	7
140	Conjunctival melanoma: New insights in tumour genetics and immunology, leading to new therapeutic options. <b>2021</b> , 100971	9
139	Inactivation of the Hippo Tumor Suppressor Pathway Promotes Melanoma.	0
138	G protein-coupled receptors can control the Hippo/YAP pathway through Gq signaling. <b>2021</b> , 35, e21668	1
137	An Updated Understanding of the Role of YAP in Driving Oncogenic Responses. <i>Cancers</i> , <b>2021</b> , 13,	6.6 5
136	A novel somatic mutation in GNB2 provides new insights to the pathogenesis of Sturge-Weber syndrome. <b>2021</b> , 30, 1919-1931	4
135	Complex interactions between the angiotensin II type 1 receptor, the epidermal growth factor receptor and TRIO-dependent signaling partners. <b>2021</b> , 188, 114521	1
134	The two sides of Hippo pathway in cancer. <b>2021</b> ,	7
133	YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance. <b>2021</b> , 475, 205-221	12
132	Crosstalk with keratinocytes causes GNAQ oncogene specificity in melanoma.	
131	The Genetics of Uveal Melanoma: Overview and Clinical Relevance. <b>2021</b> , 238, 773-780	3
130	Yes-Associated Protein in Atherosclerosis and Related Complications: A Potential Therapeutic Target That Requires Further Exploration. <b>2021</b> , 8, 704208	0

129	A serotonergic axon-cilium synapse drives nuclear signaling to maintain chromatin accessibility.	0
128	YAP facilitates melanoma migration through regulation of actin-related protein 2/3 complex subunit 5 (ARPC5). <i>Pigment Cell and Melanoma Research</i> , <b>2021</b> ,	4-5 2
127	Mechanical Strain Regulates Myofibroblast Differentiation of Human Scleral Fibroblasts by YAP. <b>2021</b> , 12, 712509	0
126	The RhoGEF Trio: A Protein with a Wide Range of Functions in the Vascular Endothelium. <b>2021</b> , 22,	1
125	The Role of G Protein-Coupled Receptor Signaling in Gynecologic Malignancy. <b>2021</b> , 57-70	
124	Hindsight: Review of Preclinical Disease Models for the Development of New Treatments for Uveal Melanoma. <b>2021</b> , 12, 4672-4685	0
123	Single-cell RNA sequencing reveals intratumoral heterogeneity in primary uveal melanomas and identifies HES6 as a driver of the metastatic disease. <b>2021</b> , 28, 1990-2000	19
122	Molecular Basis of Uveal Melanoma and Emerging Therapeutic Targets. <b>2021</b> , 3-12	
121	The landscape of GPCR signaling in the regulation of epidermal stem cell fate and skin homeostasis. <b>2020</b> , 38, 1520	3
120	Molecular Pathology and Genomics of Melanoma. <b>2020</b> , 381-422	1
119	Molecular Pathology and Genomics of Melanoma. <b>2019</b> , 1-42	1
118	Ric-8A gene deletion or phorbol ester suppresses tumorigenesis in a mouse model of GNAQ(Q209L)-driven melanoma. <b>2016</b> , 5, e236	9
117	Regulation and functions of the Hippo pathway in stemness and differentiation. <b>2020</b> , 52, 736-748	7
116	Novel therapeutic strategies and targets in advanced uveal melanoma. <b>2018</b> , 30, 134-141	13
115	Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target. <b>2021</b> , 31, 27-37	4
114	Integrin-dependent YAP signaling requires LAMTOR1 mediated delivery of Src to the plasma membrane.	2
113	YAP controls cell migration and invasion through a Rho-GTPase switch.	3
112	Uveal Melanoma Oncogene CYSLTR2 Encodes a Constitutively Active GPCR Highly Biased Toward Gq Signaling.	8

111	YAP/TAZ functions and their regulation at a glance. <b>2020</b> , 133,	88
110	Systematic genomic and translational efficiency studies of uveal melanoma. <b>2017</b> , 12, e0178189	21
109	The Role of Hippo Pathway in Cancer Stem Cell Biology. <b>2018</b> , 41, 83-92	99
108	Genetics of Uveal Melanoma. 19-35	1
107	A comprehensive evaluation of Hippo pathway silencing in sarcomas. <b>2018</b> , 9, 31620-31636	12
106	Oncotargeting G proteins: The Hippo in the room. <b>2014</b> , 5, 10997-9	13
105	FGF8 promotes colorectal cancer growth and metastasis by activating YAP1. <b>2015</b> , 6, 935-52	43
104	The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma. <b>2016</b> , 7, 23633-46	27
103	TAZ and YAP are frequently activated oncoproteins in sarcomas. <b>2016</b> , 7, 30094-108	51
102	Angiomotin stabilization by tankyrase inhibitors antagonizes constitutive TEAD-dependent transcription and proliferation of human tumor cells with Hippo pathway core component mutations. <b>2016</b> , 7, 28765-82	33
101	Minimal contribution of ERK1/2-MAPK signalling towards the maintenance of oncogenic GNAQQ209P-driven uveal melanomas in zebrafish. <b>2016</b> , 7, 39654-39670	23
100	Uveal melanoma as a target for immune-therapy. <b>2016</b> , 4, 172	46
99	Exploring Dysregulated Signaling Pathways in Cancer. <b>2020</b> , 26, 429-445	8
98	The Molecular Pathology of Eye Tumors: A 2019 Update Main Interests for Routine Clinical Practice. <b>2019</b> , 19, 632-664	4
97	The Role of Immune Checkpoint Blockade in Uveal Melanoma. <b>2020</b> , 21,	23
96	Update on uveal melanoma: Translational research from biology to clinical practice (Review). <b>2020</b> , 57, 1262-1279	10
95	Molecular characteristics of uveal melanoma and intraocular tumors. <b>2021</b> , 21, 9	1
94	The role of extracellular biophysical cues in modulating the Hippo-YAP pathway. <b>2017</b> , 50, 71-78	18

93	Regulation of Hippo signaling by actin remodeling. <b>2018</b> , 51, 151-156		65
92	Animal Models of Uveal Melanoma.. <b>2022</b> , 7,		1
91	Coexisting and Second Primary Cancers in Patients with Uveal Melanoma: A 10-Year Nationwide Database Analysis. <b>2021</b> , 10,		1
90	Potential of miRNA-Based Nanotherapeutics for Uveal Melanoma. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
89	A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer.		1
88	Endothelial p.R183Q Increases ANGPT2 (Angiopoietin-2) and Drives Formation of Enlarged Blood Vessels. <b>2021</b> , ATVBAHA121316651		0
87	Nanotechnology Addressing Cutaneous Melanoma: The Italian Landscape. <b>2021</b> , 13,		2
86	Encyclopedia of Signaling Molecules. <b>2016</b> , 1-5		
85	G-Protein $\bar{q}$ (GNAQ). <b>2017</b> , 1-5		
84	Molecular Genetics of Melanocytic Neoplasia. <b>2018</b> , 1-23		1
83	Melanomics: Comprehensive Molecular Analysis of Normal and Neoplastic Melanocytes. <b>2018</b> , 1-44		
82	Encyclopedia of Signaling Molecules. <b>2018</b> , 2230-2234		
81	Yes-associated protein (YAP) is required in maintaining normal ovarian follicle development and function.		1
80	The Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis.		
79	Genetics of Uveal Melanoma. <b>2020</b> , 81-91		
78	Multiplexed quantitative screens of single cell shape and YAP/TAZ localisation identify DOCK5 as a coincident detector of polarity and adhesion during migration.		
77	The potential role of cofilin-1 in promoting triple negative breast cancer (TNBC) metastasis via the extracellular vesicles (EVs). <b>2021</b> , 15, 101247		1
76	Uveal melanoma cells use ameoid and mesenchymal mechanisms of cell motility crossing the endothelium.		

75	Hippo signaling promotes Ets21c-dependent apical cell extrusion in the Drosophila wing disc.		
74	Genetic Landscape and Emerging Therapies in Uveal Melanoma. <i>Cancers</i> , <b>2021</b> , 13,	6.6	6
73	Verteporfin induces apoptosis and eliminates cancer stem-like cells in uveal melanoma in the absence of light activation. <b>2016</b> , 6, 2816-2830		27
72	An Insight into GPCR and G-Proteins as Cancer Drivers.. <b>2021</b> , 10,		4
71	Uveal Melanoma Metastasis. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
70	Context-dependent transcriptional regulations of YAP/TAZ in stem cell and differentiation.. <b>2022</b> , 13, 10		3
69	Targeting GPCRs and Their Signaling as a Therapeutic Option in Melanoma.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1
68	The mA reading protein YTHDF3 potentiates tumorigenicity of cancer stem-like cells in ocular melanoma through facilitating CTNNB1 translation.. <b>2022</b> ,		2
67	ROCK1 mechano-signaling dependency of human malignancies driven by TEAD/YAP activation.. <i>Nature Communications</i> , <b>2022</b> , 13, 703	17.4	0
66	The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer.. <b>2022</b> , 136, 197-222		4
65	The GNAQ T96S mutation abrogates the ability of wild-type GNAQ to induce apoptosis by phosphorylating ANXA2 in natural killer/T cell lymphoma.. <b>2022</b> ,		
64	Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling.. <b>2022</b> ,		1
63	HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma.. <b>2022</b> ,		1
62	Specific human endogenous retroviruses predict metastatic potential In uveal melanoma.. <b>2022</b> ,		1
61	Targeting Oncogenic Gβγ in Uveal Melanoma.. <i>Cancers</i> , <b>2021</b> , 13,	6.6	0
60	Rho-GEF Trio regulates osteosarcoma progression and osteogenic differentiation through Rac1 and RhoA. <b>2021</b> , 12, 1148		1
59	Crosstalk with keratinocytes causes GNAQ oncogene specificity in melanoma.. <b>2021</b> , 10,		1
58	Uveal melanoma-associated mutations in PLCβ are constitutively activating and promote melanocyte proliferation and tumorigenesis.. <b>2021</b> , 14, eabj4243		3

57	Genomic Hippo Pathway Alterations and Persistent YAP/TAZ Activation: New Hallmarks in Head and Neck Cancer.. <b>2022</b> , 11,	1
56	Overarching roles of diacylglycerol signaling in cancer development and antitumor immunity.. <b>2022</b> , 15, eabo0264	1
55	WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy.. <b>2022</b> ,	0
54	Regulator of G protein signaling 2 inhibits Gβ-dependent uveal melanoma cell growth.. <i>Journal of Biological Chemistry</i> , <b>2022</b> , 101955	5.4 0
53	Image_1.JPEG. <b>2020</b> ,	
52	Image_10.JPEG. <b>2020</b> ,	
51	Image_2.JPEG. <b>2020</b> ,	
50	Image_3.JPEG. <b>2020</b> ,	
49	Image_4.JPEG. <b>2020</b> ,	
48	Image_5.JPEG. <b>2020</b> ,	
47	Image_6.JPEG. <b>2020</b> ,	
46	Image_7.JPEG. <b>2020</b> ,	
45	Image_8.JPEG. <b>2020</b> ,	
44	Image_9.JPEG. <b>2020</b> ,	
43	Targeting-YAP/TAZ therapies for head and neck cancer, directly or indirectly?. <b>2021</b> , 39, 493-500	
42	Pathology of the Uveal Tract: Neoplasms. <b>2022</b> , 6223-6290	
41	Arrestin2 Is Critically Involved in the Differential Regulation of Phosphosignaling Pathways by Thyrotropin-Releasing Hormone and Taltirelin.. <b>2022</b> , 11,	0
40	Muscarinic Receptors Associated with Cancer.. <i>Cancers</i> , <b>2022</b> , 14,	6.6

39	MITF deficiency accelerates GNAQ-driven uveal melanoma.. <b>2022</b> , 119, e2107006119		0
38	The future of targeted kinase inhibitors in melanoma.. <b>2022</b> , 108200		0
37	In uveal melanoma G $\beta$ protein GNA11 mutations convey a shorter disease-specific survival and are more strongly associated with loss of BAP1 and chromosomal alterations than G $\beta$ protein GNAQ mutations.. <b>2022</b> , 170, 27-41		3
36	Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma.		1
35	Unraveling the Biology of Epithelioid Hemangioendothelioma, a TAZ $\beta$ TAMTA1 Fusion Driven Sarcoma. <i>Cancers</i> , <b>2022</b> , 14, 2980	6.6	
34	GNAQ and GNA11 Genes: A Comprehensive Review on Oncogenesis, Prognosis and Therapeutic Opportunities in Uveal Melanoma. <i>Cancers</i> , <b>2022</b> , 14, 3066	6.6	1
33	Extracellular Matrix Stiffness in Lung Health and Disease. 3523-3558		0
32	Structural/functional studies of Trio provide insights into its configuration and show that conserved linker elements enhance its activity for Rac1. <i>Journal of Biological Chemistry</i> , <b>2022</b> , 102209	5.4	0
31	Inactivation of the Hippo tumor suppressor pathway promotes melanoma. <i>Nature Communications</i> , <b>2022</b> , 13,	17.4	0
30	Hippo pathway regulation by phosphatidylinositol transfer protein and phosphoinositides. <i>Nature Chemical Biology</i> ,	11.7	0
29	YAP signaling is involved in WDR1-regulated proliferation and migration of non-small-cell lung cancer cells. <i>Experimental Biology and Medicine</i> , 153537022211106	3.7	
28	MITF deficiency and oncogenic GNAQ each promote proliferation programs in zebrafish melanocyte lineage cells. <i>Pigment Cell and Melanoma Research</i> ,	4.5	
27	Circular RNA hsa_circ_0007367 promotes the progression of pancreatic ductal adenocarcinoma by sponging miR-6820-3p and upregulating YAP1 expression. <b>2022</b> , 13,		0
26	Palmitoylation of GNAQ/11 is critical for tumor cell proliferation and survival in GNAQ/11-mutant uveal melanoma.		
25	Reciprocal positive regulation between BRD4 and YAP in GNAQ-mutant uveal melanoma cells confers sensitivity to BET inhibitors. <b>2022</b> , 184, 106464		0
24	Integrating Genetic Alterations and the Hippo Pathway in Head and Neck Squamous Cell Carcinoma for Future Precision Medicine. <b>2022</b> , 12, 1544		0
23	A serotonergic axon-cilium synapse drives nuclear signaling to alter chromatin accessibility. <b>2022</b> , 185, 3390-3407.e18		4
22	Signaling, Physiology, and Targeting of GPCR -Regulated Phospholipase C Enzymes. <b>2022</b> , 458-520		0



- 21 Enhanced membrane binding of oncogenic G protein  $\alpha$ Q209L confers resistance to inhibitor YM-254890. **2022**, 102538 ○
- 20 Crosstalk between Extracellular Matrix Stiffness and ROS Drives Endometrial Repair via the HIF-1 $\alpha$ /YAP Axis during Menstruation. **2022**, 11, 3162 ○
- 19 IGF1R inhibition enhances the therapeutic effects of Gq/11 inhibition in metastatic uveal melanoma progression. ○
- 18 Role of smooth muscle YAP and TAZ in protection against phenotypic modulation, inflammation, and aneurysm development. **2022**, 206, 115307 ○
- 17 Pharmacological blockade of TEAD/YAP reveals its therapeutic limitation in cancer cells. **2022**, 13, 1 ○
- 16 Crosstalk between the Hippo Pathway and the Wnt Pathway in Huntington's Disease and Other Neurodegenerative Disorders. **2022**, 11, 3631 1
- 15 YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches. ○
- 14 Functional expression of oxytocin receptors in pulp-dentin complex. **2022**, 121977 ○
- 13 Therapeutic Implications of TGF- $\beta$  Pathway in Desmoid Tumor Based on Comprehensive Molecular Profiling and Clinicopathological Properties. **2022**, 14, 5975 ○
- 12 Disruption of the interaction between mutationally activated G $\alpha$  and G $\beta$  attenuates aberrant signaling. **2023**, 102880 ○
- 11 Advances in the clinical management of uveal melanoma. 1
- 10 Targeting the secreted RGDKGE collagen fragment reduces PD-L1 by a proteasome-dependent mechanism and inhibits tumor growth. **2023**, 49, ○
- 9 Whole-genome CRISPR screening identifies PI3K/AKT as a downstream component of the oncogenic GNAQ-Focal Adhesion Kinase signaling circuitry. **2022**, 102866 ○
- 8 An Update of G-Protein-Coupled Receptor Signaling and Its Deregulation in Gastric Carcinogenesis. **2023**, 15, 736 ○
- 7 Active G $\beta\gamma$  mutants accelerate breast tumor metastasis via the c-Src pathway. ○
- 6 Therapeutic targeting of TEAD transcription factors in cancer. **2023**, 48, 450-462 ○
- 5 Cuproptosis and its application in different cancers: an overview. ○
- 4 Cell growth dilutes YAP/TAZ influencing its subcellular distribution and phenotypic heterogeneity. ○

- 3 Basis, Diagnosis, and Treatment of Uveal Melanoma. ○
- 2 Biomolecular condensates: Formation mechanisms, biological functions, and therapeutic targets. **2023**, 4, ○
- 1 FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma. **2023**, 15, 2280 ○